Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

PURPOSE: To investigate whether anti–vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line letrozole as treatment of hormone receptor–positive metastatic breast cancer (MBC). PATIENTS AND METHODS: Women with hormone receptor–pos...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Dickler, Maura N., Barry, William T., Cirrincione, Constance T., Ellis, Matthew J., Moynahan, Mary Ellen, Innocenti, Federico, Hurria, Arti, Rugo, Hope S., Lake, Diana E., Hahn, Olwen, Schneider, Bryan P., Tripathy, Debasish, Carey, Lisa A., Winer, Eric P., Hudis, Clifford A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5012690/
https://ncbi.nlm.nih.gov/pubmed/27138575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.66.1595
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados